<DOC>
	<DOCNO>NCT00056524</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety AVP-923 treatment Involuntary Emotional Expression Disorder ( IEED ) also know Pseudobulbar Affect ( episode uncontrolled cry and/or laughter ) .</brief_summary>
	<brief_title>Safety Study AVP-923 Treatment IEED ( Involuntary Emotional Expression Disorder ) Also Known Pseudobulbar Affect ( Episodes Uncontrolled Crying and/or Laughter )</brief_title>
	<detailed_description>This `` open label '' study mean placebo group . Each subject enrol study receive AVP-923 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Brain Injuries</mesh_term>
	<criteria>18 75 year age , inclusive Clinical diagnosis PBA ( pseudobulbar affect ) If female , must pregnant breast feed Sensitivity quinidine opiate drug Current prior history major psychiatric disturbance Currently participate trial within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ALS</keyword>
	<keyword>MS</keyword>
	<keyword>CNS</keyword>
	<keyword>AD</keyword>
	<keyword>TBI</keyword>
	<keyword>Dextromethorphan</keyword>
	<keyword>IEED</keyword>
	<keyword>Emotional</keyword>
</DOC>